Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Issue 2 (March 2015)

• Record Type: Journal Article
• Authors: Locatelli, Francesco; Dimkovic, Nada; Spasovski, Goce
• Is Part Of: Expert review of endocrinology & metabolism. Volume 10:Issue 2(2015)
• Page Start: 131
• Page End: 142
• Publication Date: 2015-03
• Subjects: Endocrinology -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1586/17446651.2015.1009368
• Languages: English
• ISSNs: 1744-6651

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Chronic kidney disease in the later stages poses many treatment challenges. Hyperphosphatemia is one that is well-known and is often linked to increased cardiovascular morbidity/mortality. Currently, a number of phosphate binders are available that act to conserve serum phosphate at normal or near normal levels. However, it is the overall profile of all binders that needs to be taken into account and the risks and the potential benefits associated with each agent must be balanced when selecting a particular phosphate binder. It is known that calcium-based binders, although effective phosphate binders, may lead to hypercalcemia and/or positive calcium balance and cardiovascular calcification. One, new non-calcium phosphate binder, recently approved in Europe, is colestilan. Colestilan possesses a range of properties that may afford further advantages over simply reducing serum phosphate. This review assesses the pharmacology and clinical data of colestilan used to treat hyperphosphatemia in chronic kidney disease stage 5 patients on dialysis. The article was written based on literature searches using PubMed to find articles published on phosphate binders or colestilan over the last 10 years.</p> </abstract>